LIB Therapeutics Has An Unorthodox Funding Method And Big Plans
Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers.
You may also be interested in...
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations.